JP2023546054A5 - - Google Patents

Info

Publication number
JP2023546054A5
JP2023546054A5 JP2023522409A JP2023522409A JP2023546054A5 JP 2023546054 A5 JP2023546054 A5 JP 2023546054A5 JP 2023522409 A JP2023522409 A JP 2023522409A JP 2023522409 A JP2023522409 A JP 2023522409A JP 2023546054 A5 JP2023546054 A5 JP 2023546054A5
Authority
JP
Japan
Prior art keywords
group
alkyl
ring
substituted
cases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023522409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546054A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/123515 external-priority patent/WO2022078380A1/en
Publication of JP2023546054A publication Critical patent/JP2023546054A/ja
Publication of JP2023546054A5 publication Critical patent/JP2023546054A5/ja
Pending legal-status Critical Current

Links

JP2023522409A 2020-10-13 2021-10-13 ヘテロ環glp-1アゴニスト Pending JP2023546054A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020120605 2020-10-13
CNPCT/CN2020/120605 2020-10-13
CN2021118149 2021-09-14
CNPCT/CN2021/118149 2021-09-14
PCT/CN2021/123515 WO2022078380A1 (en) 2020-10-13 2021-10-13 Heterocyclic glp-1 agonists

Publications (2)

Publication Number Publication Date
JP2023546054A JP2023546054A (ja) 2023-11-01
JP2023546054A5 true JP2023546054A5 (cg-RX-API-DMAC10.html) 2025-01-07

Family

ID=81207669

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023522409A Pending JP2023546054A (ja) 2020-10-13 2021-10-13 ヘテロ環glp-1アゴニスト

Country Status (5)

Country Link
US (1) US20240083886A1 (cg-RX-API-DMAC10.html)
EP (1) EP4229049A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546054A (cg-RX-API-DMAC10.html)
CN (1) CN116547278A (cg-RX-API-DMAC10.html)
WO (1) WO2022078380A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
JP2023538949A (ja) 2020-08-28 2023-09-12 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
JP7812052B2 (ja) 2020-09-01 2026-02-09 江蘇恒瑞医薬股▲ふん▼有限公司 縮合イミダゾール誘導体、その調製方法及びその医薬的応用
TWI843104B (zh) 2021-05-20 2024-05-21 美商美國禮來大藥廠 類升糖素肽1受體促效劑
KR20240053617A (ko) 2021-08-30 2024-04-24 민드랭크 에이아이 리미티드 Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물
KR20240056719A (ko) 2021-09-08 2024-04-30 시오노기 앤드 컴파니, 리미티드 항비만 작용이 관여하는 질환의 예방 및 치료용 의약
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US20250236627A1 (en) 2021-10-05 2025-07-24 Astrazeneca Ab Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
WO2023057427A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators
WO2023057429A1 (en) 2021-10-05 2023-04-13 Astrazeneca Ab Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
US20250066338A1 (en) 2021-12-16 2025-02-27 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
US20250042882A1 (en) 2021-12-16 2025-02-06 Astrazeneca Ab Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN119923395A (zh) * 2022-07-27 2025-05-02 卡莫特医疗有限公司 N-杂环gpcr受体激动剂、包含其的药物组合物和其使用方法
CN119907794A (zh) 2022-09-22 2025-04-29 盐野义制药株式会社 具有glp-1受体激动剂作用的稠环化合物
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
CR20250178A (es) 2022-11-16 2025-06-06 Lilly Co Eli Agonistas del receptor del péptido-1 similar al glucagón
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2686379A1 (en) * 2007-05-04 2008-11-13 Irm Llc Phenylaminopyrimidine derivatives and compositions thereof as c-kit and pdgfr kinase inhibitors
CN107207444B (zh) * 2014-11-26 2020-07-24 武田药品工业株式会社 二环化合物
CN108017636A (zh) * 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
WO2018109607A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
FI3806855T3 (fi) * 2018-06-15 2023-05-04 Pfizer Glp-1 -reseptorin agonisteja ja niiden käyttöjä
EA202191432A1 (ru) * 2018-11-22 2021-10-14 Цилу Регор Терапьютикс Инк. Агонисты glp-1r и их применения
ES3029360T3 (en) * 2019-11-15 2025-06-24 Ildong Pharmaceutical Co Ltd Glp-1 receptor agonist and use thereof

Similar Documents

Publication Publication Date Title
JP2023546055A5 (cg-RX-API-DMAC10.html)
JP2023537501A5 (cg-RX-API-DMAC10.html)
JP2023524493A5 (cg-RX-API-DMAC10.html)
JP2023515404A5 (cg-RX-API-DMAC10.html)
JP2023538949A5 (cg-RX-API-DMAC10.html)
JP2023513272A5 (cg-RX-API-DMAC10.html)
JP2023540558A5 (cg-RX-API-DMAC10.html)
US20230201185A1 (en) Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
RU2345067C2 (ru) Ингибиторы дпп-iv
JP2023540609A5 (cg-RX-API-DMAC10.html)
JP2025506473A5 (cg-RX-API-DMAC10.html)
US9382229B2 (en) Compounds and methods of use thereof for treating neurodegenerative disorders
US20240294525A1 (en) Compounds as glp-1 receptor agonists and uses thereof
JP7769695B2 (ja) Glp-1rアゴニストの結晶形態およびその使用
US20170088532A1 (en) Inhibitors of lpxc
US20130023522A1 (en) Benzamides
CA2889697C (en) Cannabinoid receptor mediating compounds
CA2657350A1 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
US9238074B2 (en) Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
JP2009501776A (ja) 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用
JP2010504321A5 (cg-RX-API-DMAC10.html)
TW201418250A (zh) 含有雜環的5-羥基吲哚類衍生物及其用途
CN117337281A (zh) 作为可溶性环氧化物水解酶抑制剂的哌啶脲衍生物
JP3410476B2 (ja) 新規なエポキシコハク酸アミド誘導体又はその塩
CN1228325C (zh) 双胍衍生物